Patients’ Characteristics
| Characteristic | Total | PET-positive | PET-negative |
| Patients (n) | 172 | 120 | 52 |
| Age (y), median | 70 (46–86) | 70 (46–86) | 70 (47–80) |
| PSA at PET (ng/mL), median | |||
| PSA recurrence | 0.44 (0.15–6.24) | 0.78 (0.27–6.24) | 0.3 (0.15–3.24) |
| PSA persistence | 1.2 (0.13–40.13) | 1.9 (0.14–40.13) | 0.34 (0.13–1.33) |
| Definitive radiotherapy | 13.6 (0.14–150) | 13.7 (0.14–150) | 0.52 |
| Gleason score* | |||
| ≤6 | 12 | 9 | 3 |
| 7a | 34 | 21 | 13 |
| 7b | 40 | 25 | 15 |
| ≥8 | 81 | 61 | 20 |
| Unknown | 5 | 4 | 1 |
| TNM | |||
| T1c | 36 | 26 | 10 |
| T2b | 2 | 2 | 0 |
| T2c | 2 | 2 | 0 |
| T3a | 5 | 5 | 0 |
| T3b | 5 | 5 | 0 |
| Tx | 122 | 80 | 42 |
| N0 | 85 | 57 | 28 |
| N1 | 9 | 9 | 0 |
| Nx | 78 | 54 | 24 |
| M0 | 165 | 113 | 52 |
| M1a | 4 | 4 | 0 |
| M1b | 3 | 3 | 0 |
| D’Amico classification | |||
| Low | 5 | 3 | 2 |
| Intermediate | 21 | 13 | 8 |
| High | 146 | 104 | 42 |
| Radiotherapy indication | |||
| PSA recurrence | 62 | 31 | 31 |
| PSA persistence | 88 | 68 | 20 |
| Definitive radiotherapy | 22 | 21 | 1 |
↵* Data on Gleason score were obtained from biopsy in treatment-naïve patients and from radical prostatectomy in postoperative patients.
Data in parentheses are ranges.